Chamber and committees

The information requested on how many full-time equivalent administrative support posts provide support to consultants across the NHS is not centrally available.

Since Sept 2007, administrative services have increased by 21.5% or by 5,316.9 WTE, from 24,737.2 WTE as at Sept 2007 to 30,054.1 WTE as at Dec 2023.

Support to clinical staff, up 45.4% since Sept 2007 to 9,600.5 WTE as at Dec 2023.

Further Information on the administrative services workforce, can be found on the TURAS NHS Education for Scotland workforce statistics site at: 05 March 2024 Workforce | Turas Data Intelligence (nhs.scot)

The information that has been requested is not held centrally by the Scottish Government.

The information requested on how many cancer nurses have been employed in each year since 2011-12, broken down by NHS board area is not centrally available.

In the context of specialist provision of gender identity healthcare to children and young people, since publication of its Strategic Action Framework for Gender Identity Service improvement in December 2021, the Scottish Government has maintained an extensive dialogue with NHS Health Boards in Scotland on how to collectively work to improve healthcare provision in this sphere.

On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.

The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.

The term “puberty-suppressing hormones” is non-specific, and could be applied to a range of medicines used for a variety of conditions.

The Scottish Government and NHS Scotland are proactively engaged with NHS England and its commissioned research study on puberty-suppressing hormones as a treatment option for gender dysphoria. This is being delivered by the National Institute for Health Research (NIHR). The Scottish Government and the NHS in Scotland are currently observers to that ongoing study development process, however consideration by NHS partners of what further engagement with this study may be appropriate is ongoing, as the scope of the research continues to be developed and defined by NIHR.

Parliamentary business is a matter for the Scottish Parliament’s Parliamentary Bureau and the Parliament itself.

The Scottish Government has had no recent discussions with the UK Government regarding Port of Cairnryan Ltd’s submission of company accounts for the year to 31 December 2022.

The Scottish Government is grateful for the latest advice from the Climate Change Committee and remains fully committed to delivering net zero by 2045. As published alongside the statement to the Chamber on the Climate Change Bill, we will develop measures to accelerate the switch from ICE to zero emission vans and other vehicles in order to help reduce ICE van kms, with the intention of achieving early progress with the largest companies while ensuring appropriate support mechanisms for smaller businesses and independent traders.

We will carefully consider the report’s recommendations in relation to van traffic and provide a response in due course.

While the Scottish Government sets the strategic policy for the NHS in Scotland, legal responsibility for service delivery rests locally with Health Boards and their healthcare professionals. As part of the service redesign under the GP contract, the focus is on reconfiguring a number of services at scale, across the country, including Vaccinations and Community Treatment & Care services. The Scottish Government did not stipulate delivery models; Health Boards, Integration Authorities and Local Medical Committees have been asked to work together to design services which will meet the needs of patients in their areas, including accessibility.

The final report from the NHS England-commissioned Independent Review of Gender Identity Services for Children and Young People (the ‘Cass Review’), chaired by Dr Hiliary Cass, was published on 10 April. The Cass Review did not review or consider clinical services as offered by Health Boards in Scotland.

However, both the Scottish Government and Scottish Health Boards had continued to proactively engage with the Cass Review as it progressed, to share information on improvement work in Scotland; shared learning; best practice; and to understand outputs of the review in England.

The Scottish Government welcomes the final report of the Cass Review, and we are now closely considering its findings at pace. Health Boards will also be considering the content of the report in the context of how this type of healthcare is delivered within Scotland.

On 18 April, in a joint statement, NHS Greater Glasgow and Clyde and NHS Lothian confirmed that both Boards have paused any new prescription of puberty-supressing hormones and cross-sex hormones for young people as a treatment option for gender dysphoria.

The small number of patients directly impacted by this change, and their families, were notified in advance of this statement. It is right that they were the first to hear about it, sensitively and from the services caring for them, before a public statement was made.